Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...

Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.

India's Coronavirus Vaccine Market offers growth through government-led initiatives, robust manufacturing, and R&D in vaccine ...

Novavax (($NVAX)) has held its Q3 earnings call. Read on for the main highlights of the call. Novavax’s Q3 2025 Earnings Call: A Cautiously ...

Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...

Gaithersburg-based Novavax raised its annual revenue forecast, banking on milestone payments from vaccine supply and licensing deals.

Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 as the biotech awaits key product launches from its partnership with ...

Pfizer (PFE) stock is in focus as the company exceeds Street forecasts with its Q3 2025 results thanks mainly to its COVID ...

President Donald Trump has received updated flu and COVID-19 booster shots in preparation for upcoming travel, the president’s physician announced Oct. 10. Sean P. Barbabella, a U.S. Navy captain, ...

The 2025-2026 respiratory viral season is approaching.With it comes the familiar challenge of protecting our most vulnerable ...

It's officially the season of text prompts and phone call reminders to get your seasonal vaccines. Cases of flu, RSV, COVID-19, and other common respiratory illnesses tend to spike as temperatures go ...